Panel Detail

Sunday, September 9, 2012
10:40 AM - 11:30 AM

The Coming Age of Precision Medicine


Jeff Allen, Executive Director, Friends of Cancer Research
Carl June, Director, Translational Research, Abramson Cancer Center; Richard W. Vague Professor of Immunotherapy, Perelman School of Medicine, University of Pennsylvania
Tomas Philipson, Senior Fellow, Milken Institute; Daniel Levin Professor of Public Policy Studies, Irving B Harris Graduate School of Public Policy Studies, University of Chicago
Nathan Price, Associate Professor, Institute for Systems Biology
Max Wicha, Distinguished Professor of Oncology; Director, University of Michigan Comprehensive Cancer Center


Andrew von Eschenbach, President, Samaritan Health Initiatives Inc.; former Commissioner, U.S. Food and Drug Administration; former Director, National Cancer Institute
In the 1990s, it was estimated that sequencing a single human genome would cost $3 billion and take more than a decade. The cost of mapping an individual human genome may break the $1,000 barrier by the end of the year. This opens up the ability to deliver the right medicine to the right patient at the right time. Panelists will analyze the mysteries of the human genome and practical ways to use this information. How can clinicians reinvent the way they evaluate signs and symptoms of disease and instead base diagnosis on underlying molecular causes? How do we ensure the scientific trajectory toward more personalized treatments will not be squelched by the countervailing pressure to pay only for treatments deemed most effective in large populations of patients?

Panel Video

th precisionmedicine

Click image above to play video